Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.
BMS's Opdivo has been rejected by NICE for use in patients with advanced lung cancer, the cost-effectiveness watchdog saying its price is too high to merit routine use.
By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback